Aurobindo Pharma arm’s biosimilar gets Health Canada NOC
Image used for representational purposes. Photo credits: Special Arrangement Aurobindo Pharma subsidiary CuraTeQ Biologics has received notice of compliance (NOC) from Health Canada’s Biologics and Radiopharmaceutical Drugs Directorate for Dyrupeg, its pegylated filgrastim biosimilar version. A notice of compliance from Health Canada is issued to a drug manufacturer after a successful review, confirming the product…
Read More “Aurobindo Pharma arm’s biosimilar gets Health Canada NOC” »